| Jun 3 |
Summit Therapeutics raises $200M; expands license territories for ivonescimab
|
| Jun 3 |
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
|
| Jun 1 |
Summit lead asset approved in China for lung cancer
|
| Jun 1 |
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
|
| May 31 |
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
|
| May 31 |
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
|
| May 31 |
Summit Therapeutics Stock: Plunging Despite A Win?
|
| May 31 |
Summit pares gains as ‘China-only’ trial beats Merck’s Keytruda
|
| May 31 |
Summit reports data from Phase III NSCLC treatment trial
|
| May 30 |
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
